<DOC>
	<DOCNO>NCT02076841</DOCNO>
	<brief_summary>To evaluate treatment tolerability , adherence quality life ( QoL ) 1 year MS ( Multiple Sclerosis ) participant switch - due persistent tolerability issue , particularly injection problem - subcutaneous injectable disease-modifying treatment ( DMT ) give several time week ( Rebif , Betaferon Copaxone ) weekly Avonex 30 μg give intra-muscularly . Avonex apply injection device Avonex Pen .</brief_summary>
	<brief_title>Tolerability Quality Life Study Participants Who Switched Avonex Pen</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Key Continuous treatment Rebif , Betaferon Copaxone least past year . Injections site tolerability issue document medical record nurse inclusion . Clinically stable ( free relapse 6month confirmed disability progression least 6 month ) therapy . Documented neurological history least year prior study entry . Qualification Avonex® ( Avonex Pen ) accord approve indication ( Clinical Isolated Syndrome ) Relapsing Remitting Multiple Sclerosis ( RRMS ) . Acceptance magnetic resonance imaging . Key Patients previously enter study . Treatment Avonex 12 month prior study . One relapse and/or 6month confirmed disability progression 6 month prior study . Patient Betaferon Neutralizing Antibodies ( NAbs ) 400 TRU ( tenfold reduction unit ) patient Rebif NAbs 100 TRU . Secondary progressive multiple sclerosis . Primary progressive multiple sclerosis . Pregnancy breast feed . History severe depression attempt suicide current suicidal ideation . Medical psychiatric condition compromise ability give inform consent , comply protocol , complete study . Uncontrolled seizure disorder . Myopathy clinically significant liver disease . Inability , opinion principal investigator staff , comply protocol requirement duration study . Known hypersensitivity interferonbeta human proteins include albumin . A history drug abuse 6 month prior screen . Treatment follow 30 day day 1 : systemic corticosteroid , ACTH , investigational drug . Participation study involve investigational market product , concomitantly within 30 day prior entry study . Likelihood require treatment study period drug permit study protocol . NOTE : Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>